Life Spine commenced alpha launch of the SENTRYâ„¢ ALIF Plating System, designed to omit the need for posterior stabilization with anterior lumbar interbody fusion.Â
Anika Therapeutics received Australia regulatory approval to market MONOVISC® single-injection viscosupplement for the treatment of osteoarthritis pain in all synovial joints.Â
NuVasive received expanded FDA 510(k) clearance of the TLX™ interbody fusion system, including an expandable 20° cage, use with allogeneic bone graft and use in additional levels of the spine.
ORTHOWORLD estimates that global orthobiologic product sales account for ~10% of the orthopaedic market's revenue, overall. In 2016, that translated to just over $4.9 billion, an increase of 3% vs. 2015. For 2017 and into 2019, we're projecting similar growth.